Elara Pharmaceuticals Frequently Asked Questions (FAQ)
What is Elara Pharmaceuticals's latest funding round?
Elara Pharmaceuticals's latest funding round is Grant.
How much did Elara Pharmaceuticals raise?
Elara Pharmaceuticals raised a total of $6.4M.
Who are the investors of Elara Pharmaceuticals?
Investors of Elara Pharmaceuticals include BMBF GOBio, BioRN - Biotechnologie Rhein-Neckar, Wagnisfinanzierungsgesellschaft fuer Technologiefoerderung in Rheinland-Pfalz, KfW and EMBL Ventures.
Who are Elara Pharmaceuticals's competitors?
Competitors of Elara Pharmaceuticals include Kythera Biopharmaceuticals, Idenix Pharmaceuticals, ugichem, Callisto Pharmaceuticals, Excaliard Pharmaceuticals and 13 more.
Compare Elara Pharmaceuticals to Competitors
Inflazyme Pharmaceuticals is a biopharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of respiratory and inflammatory diseases. The company's core focus is medicinal chemistry based, orally active, small molecules aimed at treating unmet medical needs.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Affibody is a private clinical-stage biotech company. It specializes in the discovery of antibody mimetics that provide biodistribution flexibility, tissue penetration, and tumor targeting. The company was founded in 1998 and is based in Solna, Sweden.
Sound Pharmaceuticals (SPI) is a biopharmaceutical company that develops prescription drugs that will enable doctors and patients to prevent and treat hearing loss, a disease that affects over 30 to 40 million Americans. It was founded in 2002 and is based in Seattle, Washington.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
greenovation Biotech GmbH is engaged in the production of pharmaceutically highly-efficient glycoproteins